Greenwich LifeSciences flags release with FLAMINGO-01 clinical update
PUBT · 1d ago
Share
Listen to the news
- Greenwich LifeSciences posted clinical updates on its Phase III FLAMINGO-01 trial of GLSI-100 to prevent breast cancer recurrences.
- DSMB review in May 2026 recommended the study continue without modification.
- Trial redesign targets HR 0.55; interim analyses at 28 events, 56 events; study end at 133 events; enrollment may run up to 2,000 patients.
- Protocol change expands eligibility beyond HLA-A*02; company expects a 2.22x faster enrollment rate.
- Q2 2026 burn rate expected near $2 million; cash balance estimated at $8.9 million as of June 30, 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Greenwich Lifesciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607200600PRIMZONEFULLFEED9764584) on July 20, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending